SCHEMBL689184

SCHEMBL689184

O=CNOCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
ADH1B P00325 1/20 0.48
ADH1C P00326 1/20 0.48
ADH1A P07327 1/20 0.48
ADH7 P40394 1/20 0.48
TSHR P16473 2/20 0.46
EPHX1 P07099 1/20 0.44
IDO1 P14902 1/20 0.43
AGXT P21549 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
TAAR1 Q96RJ0 1/20 0.41
BCHE P06276 1/20 0.41
ALDH1A1 P00352 2/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
CCNB2 O95067 1/20 0.41
CDK1 P06493 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6944557 0.98 NPC1 (0.47) NPC1RAB9AADH1BADH1CADH1A
Bromide SCHEMBL38656295 0.98 NPC1 (0.47) NPC1RAB9AADH1BADH1CADH1A
Ammonia Solution, Strong SCHEMBL28447660 0.98 NPC1 (0.47) NPC1RAB9AADH1BADH1CADH1A
SCHEMBL21776500 0.98 NPC1 (0.47) NPC1RAB9AADH1BADH1CADH1A
SCHEMBL27952705 0.98 NPC1 (0.47) NPC1RAB9AADH1BADH1CADH1A
Methacrylic Acid SCHEMBL27804888 0.85 ALDH1A1 (0.46) NPC1RAB9AALDH1A1MAOB
SCHEMBL22556262 0.81 HTR2A (0.42) ADH1BADH1CADH1AADH7TSHR
SCHEMBL13477514 0.79 LOXL2 (0.37) KMT2AALDH1A1
SCHEMBL18661137 0.79 TPSAB1 (0.41) NPC1RAB9ACA1CA2CA9
SCHEMBL13477426 0.79 KMT2A (0.51) NPC1RAB9AIDO1AGXTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 488 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111960997-B Method for synthesizing hydroxyalkyl substituted quinoline derivatives 浙江工业大学 2021-10-12 CN claimed
CN-111960997-A Method for synthesizing hydroxyalkyl substituted quinoline derivatives 浙江工业大学 2020-11-20 CN claimed
US-9487494-B2 Cyclic hydrocarbon compounds for the treatment of diseases LEO PHARMA A/S (DK) 2016-11-08 US claimed
CN-105753726-A Preparation method for asymmetrical synthesis of pregabalin 深圳市华先医药科技有限公司 2016-07-13 CN claimed
EP-1730152-B1 TETRAHYDROQUINOLINE DERIVATIVES AND A PROCESS FOR PREPARING THE SAME MITSUBISHI TANABE PHARMA CORP (JP) 2012-05-02 EP claimed
EP-1975158-B9 NOVEL PYRROLE DERIVATIVES WITH HISTONE DEACETYLASE INHIBITOR ACTIVITY UNIV PAIS VASCO (ES) 2012-02-29 EP claimed
US-20110319293-A1 SYNTHETIC PROTEASE SUBSTRATES, ASSAY METHODS USING SUCH SUBSTRATES AND KITS FOR PRACTICING THE ASSAY LIFESENSORS, INC. 2011-12-29 US claimed
EP-1975158-B1 NOVEL PYRROLE DERIVATIVES WITH HISTONE DEACETYLASE INHIBITOR ACTIVITY UNIV PAIS VASCO (ES) 2011-07-13 EP claimed
US-7879887-B2 such as 2-(4-chloro-3-hydroxyphenylamino)-N-(6H-pyrazolo[4',3':3,4]benzo[1,2-d]thiazol-2-yl)-acetamide, having antitumor activity, particularly dual inhibitory activity on Aurora kinase and cyclin-dependent kinase (CDK), and are useful for cell proliferative diseases such as cancer NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2011-02-01 US claimed
US-20100317582-A1 NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2010-12-16 US claimed
CN-1017800-B TRICYCLIC COMPOUNDS HOFFMANN LA ROCHE (CH) 1992-08-12 CN claimed
EP-0497192-A2 Amino acid derivatives F. HOFFMANN-LA ROCHE AG (CH) 1992-08-05 EP claimed
EP-0471609-A1 Benzofuran Derivatives, Benzothiophenes, Indoles or Indolizines, Process for Production and Compositions containing them SANOFI (FR) 1992-02-19 EP claimed
EP-0173956-A1 Sulfonyl-guanidinotriazine derivatives BAYER AG (DE) 1986-03-12 EP claimed
EP-0173317-A1 Unsymmetrical sulfonyl guanidines BAYER AG (DE) 1986-03-05 EP claimed
EP-0173321-A1 Sulfonyl-guanidinopyrimidine derivatives BAYER AG (DE) 1986-03-05 EP claimed
US-4436921-A CARCINOSTATIC ACTIVITY TOYAMA CHEMICAL CO., LTD. (JP) 1984-03-13 US claimed
EP-0018063-B1 PYRIDAZIN (2H)-3-ONES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN ANTIHYPERTENSIVE AGENTS DIAMOND SHAMROCK CORPORATION (US) 1983-02-23 EP claimed
US-4238490-A Antihypertensive pyridazin(2H)-3-ones DIAMOND SHAMROCK CORPORATION (US) 1980-12-09 US claimed
EP-0018063-A1 Pyridazin (2H)-3-ones, process for their preparation and their use in antihypertensive agents DIAMOND SHAMROCK CORPORATION (US) 1980-10-29 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317582-A1 NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES ARNT, AHR, CYP27A1 NPC1 190/4885RAB9A 4614/4885ADH1B 532/4885
US-20110319293-A1 SYNTHETIC PROTEASE SUBSTRATES, ASSAY METHODS USING SUCH SUBSTRATES AND KITS FOR PRACTICING THE ASSAY SENP1, STUB1, SENP7 NPC1 2546/4885RAB9A 3109/4885ADH1B 3939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.